Medicare Enrolled
Dr. Robert Wang, M.D.
Ophthalmology · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Wang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Wang?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Wang
Dr. Robert Wang is an ophthalmology specialist in Dallas, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Wang performed 74,847 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Wang received a total of $159,094 from 29 pharmaceutical and/or device companies across 423 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Wang is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 1% volume in TX
$159,094 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗74,847
Medicare services
Top 1% in TX for ophthalmology
Not available
Unique patients (not deduplicated)
$46
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Eye injection (Vabysmo/faricimab) An injection of faricimab-svoa, a medication administered in 0.1 mg doses. |
63,555 | $27 | $79 |
| Retinal imaging (OCT scan) This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye. |
2,836 | $30 | $100 |
| Eye injection for retinal disease A procedure involving the administration of medication directly into the eye. |
1,537 | $94 | $1,186 |
| Comprehensive eye exam, established patient A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider. |
1,024 | $87 | $200 |
| Aflibercept eye injection (Eylea) | 989 | $676 | $2,220 |
| Triamcinolone acetonide injection, 1 mg An injection of triamcinolone acetonide, a corticosteroid medication, administered in a 1 mg dose. |
976 | $34 | $102 |
| Pegcetacoplan intravitreal injection, 1 mg An injection of pegcetacoplan administered into the vitreous humor of the eye. The dose specified is 1 milligram. |
840 | $120 | $333 |
| Dexamethasone intravitreal implant injection An injection of a dexamethasone implant placed inside the eye. This procedure delivers medication directly into the vitreous cavity of the eye. |
743 | $146 | $412 |
| Eye exam, established patient, focused A limited examination of the visual system for an existing patient. The provider focuses on a specific eye-related concern or symptom. |
658 | $68 | $200 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
456 | $59 | $110 |
| Injection, ranibizumab, 0.1 mg | 265 | $184 | $500 |
| Comprehensive eye exam, new patient A comprehensive examination of the visual system performed for a new patient. |
196 | $104 | $275 |
| Retinal angiography with dye injection This procedure uses a special camera to examine the blood vessels in the retina after a dye has been injected into the body. |
156 | $101 | $285 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
153 | $84 | $170 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
113 | $1,872 | $6,034 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
101 | $128 | $240 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
60 | $118 | $280 |
| New patient office visit, complex (60-74 min) | 50 | $164 | $350 |
| Retinal membrane and internal limiting membrane removal A surgical procedure to remove a membrane from the retina along with the internal limiting membrane of the retina. |
30 | $907 | $5,700 |
| Vitreous removal between lens and retina This procedure involves the removal of the vitreous fluid located between the lens and the retina of the eye. |
26 | $711 | $4,000 |
| Retinal laser treatment for leaking blood vessels This procedure uses a laser to seal leaking blood vessels in the retina. It is performed to prevent vision loss caused by fluid leakage from damaged retinal vessels. |
16 | $289 | $3,000 |
| Removal of retinal membrane A surgical procedure to remove a membrane from the surface of the retina. |
15 | $905 | $5,500 |
| Retinal detachment repair with fluid drainage A surgical procedure to reattach a detached retina by draining excess fluid from the space between the lens and the retina. |
14 | $851 | $6,000 |
| Visual field test, extended A test that maps your complete field of vision to detect blind spots or peripheral vision loss. Extended testing provides a more detailed assessment than a standard visual field exam. |
13 | $46 | $150 |
| Retinal photography (fundus photo) This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures. |
13 | $29 | $165 |
| Ultrasound of eye tissue and structures A diagnostic imaging test that uses sound waves to create pictures of the eye's internal tissues and structures. |
12 | $39 | $305 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$159,094
Total received (2018-2024)
Avg $22,728/year across 7 years
Top 2% in TX for ophthalmology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
29
Companies
423
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$11,470
2023
$17,054
2022
$18,085
2021
$8,210
2020
$15,245
2019
$42,963
2018
$46,068
Payments by company (2024)
Bausch & Lomb Americas Inc.
$6,176
Alimera Sciences, Inc.
$2,780
Genentech USA, Inc.
$1,006
Apellis Pharmaceuticals, Inc.
$376
Regeneron Healthcare Solutions, Inc.
$284
Astellas Pharma Global Development
$218
ANI Pharmaceuticals, Inc.
$194
Genentech, Inc.
$102
Astellas Pharma US Inc
$94
ABBVIE INC.
$78
Sandoz Inc.
$74
Mallinckrodt Hospital Products Inc.
$59
Coherus Biosciences Inc.
$28
Top 3 companies account for 86.8% of 2024 payments
All-time payments by company (2018-2024) ›
Mallinckrodt Enterprises LLC
$27,750
AbbVie, Inc.
$25,538
EyePoint Pharmaceuticals US, Inc.
$23,931
Mallinckrodt LLC
$22,332
Bausch & Lomb Americas Inc.
$19,732
Mallinckrodt Hospital Products Inc.
$18,298
Genentech USA, Inc.
$10,425
Alimera Sciences, Inc.
$4,336
Bausch & Lomb, a division of Bausch Health US, LLC
$1,655
Novartis Pharmaceuticals Corporation
$1,404
Apellis Pharmaceuticals, Inc.
$592
Genentech, Inc.
$498
Regeneron Healthcare Solutions, Inc.
$432
Coherus Biosciences Inc.
$401
ABBVIE INC.
$334
ANI Pharmaceuticals, Inc.
$287
Astellas Pharma Global Development
$218
AbbVie Inc.
$173
NotalVision
$141
Horizon Therapeutics plc
$122
Allergan, Inc.
$99
Astellas Pharma US Inc
$94
OPTOS, INC.
$82
Sandoz Inc.
$74
Exeltis, USA Inc.
$60
VYERA PHARMACEUTICALS, LLC
$33
Vyera Pharmaceuticals, LLC
$21
Kala Pharmaceuticals, Inc.
$19
Eyevance Pharmaceuticals LLC
$14
Top 3 companies account for 48.5% of all-time payments
Associated products mentioned in payments ›
ACTHAR · Actemra · BEOVU · Cimerli · DEXYCU · DOCTORS ALLERGY FORMULA · Daraprim · Daraprim Tablet 25mg · EYLEA · EYLEA AFLIBERCEPT INJECTION · EYLEA HD · EYP-1901 · Enspryng · ForeseeHome · HUMIRA · Humira · ILUVIEN · INVELTYS · Iluvien · Izervay · LOTEMAX GEL · Lucentis · Monaco · OZURDEX · PURIFIED CORTROPHIN GEL · RETISERT · RINVOQ · SUSVIMO · Susvimo · Syfovre · TEPEZZA · Tobradex ST · VABYSMO · VISUDYNE · VYZULTA · Vabysmo · XIPERE · YUTIQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Ophthalmologists in nearby ZIP areas
285
County median income
$74,149
Nearest hospital to ZIP centroid (approximate)
TEXAS HEALTH PRESBYTERIAN HOSPITAL DALLAS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Wang is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Wang experienced with eye injection (vabysmo/faricimab)?
Based on Medicare claims data, Dr. Wang performed 63,555 eye injection (vabysmo/faricimab) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Wang receive payments from pharmaceutical companies?
Yes. Dr. Wang received a total of $159,094 from 29 companies across 423 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Wang's costs compare to other ophthalmologists in Dallas?
Dr. Wang's average Medicare payment per service is $46. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Wang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Ophthalmologists in Dallas
Browse ophthalmologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Ophthalmologists in TX
Ophthalmologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Ophthalmologists in TX
Which TX ophthalmologists receive the most from drug and device companies.
By company
Mallinckrodt Enterprises LLC Payments to Doctors
See all physicians who received payments from Mallinckrodt Enterprises LLC.
By company
AbbVie, Inc. Payments to Doctors
See all physicians who received payments from AbbVie, Inc.
By company
EyePoint Pharmaceuticals US, Inc. Payments to Doctors
See all physicians who received payments from EyePoint Pharmaceuticals US, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology